Steve Young
Chief Tech/Sci/R&D Officer at ARCUS BIOSCIENCES, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Juan Jaen | M | 66 |
Flexus Biosciences, Inc.
 Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | 22 years |
| William Rieflin | M | 64 |
Flexus Biosciences, Inc.
Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA.
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 18 years |
| Terry Rosen | M | 65 |
Flexus Biosciences, Inc.
Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | 20 years |
| Robert Bradway | M | 61 | 18 years | |
| Andrew Perlman | M | 76 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 16 years |
| David Lacey | M | 71 | 22 years | |
| Jennifer Jarrett | F | 53 | 7 years | |
| Robert Goeltz | M | 51 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 7 years |
| Brian Wong | M | 52 | 9 years | |
| Clarence Machado | M | 60 | 5 years | |
| Alexander Azoy | M | 48 | 4 years | |
| Esteban Santos | M | 56 | 17 years | |
| Nicole Lambert | F | 50 | 3 years | |
| David Reese | M | 61 | 19 years | |
| Matthew Busch | M | 50 | 20 years | |
| Antoni Ribas | M | 57 | 5 years | |
| Kathryn Falberg | F | 63 | 7 years | |
| Tyler Jacks | M | 63 | 12 years | |
| Andrew Nix | M | - |
University of Bristol
| 35 years |
| Yasunori Kaneko | M | 69 | 9 years | |
| Ronald Sugar | M | 75 | 14 years | |
| Holli Kolkey | M | - | - | |
| Rachna Khosla | F | - | 11 years | |
| Eric Matthews | M | - | 5 years | |
| Dimitry Nuyten | M | - | 2 years | |
| Yvonne Gehring | F | - | 8 years | |
| Carolyn Tang | F | 45 | 7 years | |
| Johanna Mercier | F | 54 | - | |
| Merdad Parsey | M | 61 | 4 years | |
| Jonathan Yingling | M | 55 | 4 years | |
| Linda Higgins | M | 62 | 3 years | |
| William Ho | M | 58 | 9 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David W. Beier | M | 75 | 10 years | |
| David Goeddel | M | 72 |
Flexus Biosciences, Inc.
Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | 8 years |
| Pamela Wapnick | F | 58 | 9 years | |
| Jason Barker | M | 54 | 1 years | |
| Paul Eisenberg | M | - | 14 years | |
| Kevin Sharer | M | 76 | 20 years | |
| Dennis Fenton | M | 72 | 27 years | |
| Marc M. P. de Garidel | M | 66 | 15 years | |
| Steven McKnight | M | 75 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 13 years |
| Michael Severino | M | 58 | 10 years | |
| Gregory L. Tewalt | M | - | - | |
| Craig Shepherd | M | - | 7 years | |
| Cynthia Patton | F | 62 | 15 years | |
| Raymond C. Jordan | M | 70 | 7 years | |
| Diana McKenzie | F | 59 | 12 years | |
| Thomas Zindrick | M | 65 | 8 years | |
| Marco Renoldi | M | 67 | 3 years | |
| Vasant Prakash Gandhi | M | - | 5 years | |
| Annette L. Such | F | 55 | - | |
| Rekha Hemrajani | F | 54 | - | |
| Sean B. W. Martin | M | 61 | - | |
| Yi Ning Zhao | M | 53 | 9 years | |
| Laurie Stelzer | F | 56 | 2 years | |
| Robert Azelby | M | 56 | 5 years | |
| Joseph Newell | M | 54 | 7 years | |
| Susan Lundeen Smuck | F | 57 | 12 years | |
| Andreas Grauer | M | 63 | - | |
| Melissa C. Paoloni | M | - | 4 years | |
| Michael Quigley | M | 42 | - | |
| Nathan Hardy | M | 48 | 10 years | |
| Rachel Lenington | F | 51 | 10 years | |
| Carla Daniel | F | - |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 6 years |
| John Moriarty | M | 56 | 6 years | |
| Leonard Schaeffer | M | 78 | 9 years | |
| George Morrow | M | 72 | 10 years | |
| J. Reason | M | 83 | 12 years | |
| David J. Scott | M | 71 | - | |
| Beth Seidenberg | M | 67 | 8 years | |
| Rebecca M. Henderson | M | 63 | 11 years | |
| Timothy Martin | M | 55 | 3 years | |
| Kristen Hege | M | 60 | 1 years | |
| Dominique Monnet | M | 65 | 11 years | |
| Frank Herringer | M | 81 | 15 years | |
| Vance D. Coffman | M | 79 | 9 years | |
| Frederick Gluck | M | 88 | 13 years | |
| James Daly | M | 63 | 9 years | |
| Patricia Cary Sueltz | F | 71 | 2 years | |
| Pieter B. M. W. M. Timmermans | M | 74 |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | 8 years |
| Preston Klassen | M | 55 | 7 years | |
| Stuart Green | M | 58 |
University of Bristol
| 6 years |
| Steven Galson | M | 67 | - | |
| William Ashton | M | 73 | 16 years | |
| William P. Sheridan | M | 69 | 5 years | |
| Cynthia Flowers | F | 64 | 5 years | |
| François de Carbonnel | M | 78 | 10 years | |
| Jin Long Chen | M | 61 | 4 years | |
| John Smither | M | 71 | 6 years | |
| Laura Fletcher | M | - |
University of Bristol
| 7 years |
| Yujiro Hata | M | 49 |
Flexus Biosciences, Inc.
Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | 1 years |
| Thomas Johannes W. Dittrich | M | 60 | 4 years | |
| Christopher Nardecchia | M | 62 | 11 years | |
| David Essayan | M | - | 4 years | |
| Holger Wesche | M | 56 | 2 years | |
| Reshma Kewalramani | M | 51 | 13 years | |
| Adam Hale | M | 59 |
University of Bristol
| 3 years |
| Kern Chua | M | 53 |
University of Bristol
| 4 years |
| David A. Piacquad | M | 67 | 12 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 94 | 94.95% |
| United Kingdom | 5 | 5.05% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Steve Young
- Personal Network
